CTOs on the Move

Viracta

www.viracta.com

 
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.viracta.com
  • 2533 South Coast Highway 101 Suite 210
    Cardiff, CA USA 92007
  • Phone: 858.400.8470

Executives

Name Title Contact Details

Funding

Viracta raised $10M on 12/04/2018
Viracta raised $65M on 02/24/2021
Viracta raised $50M on 11/05/2021

Similar Companies

CAPARIO

CAPARIO is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scorpion Therapeutics

Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.

Puma Biotechnology

We focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

Lineage Cell

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.

Bio-Kinetic Clinical Applications

Bio-Kinetic Clinical Applications is a Springfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.